Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs Seladelpar (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 06 Nov 2018 According to a Cymabay Therapeutics media release, recruitment in this trial is one quarter ahead of schedule and is now expected to be fully enrolled in the first quarter of 2019.
    • 11 Jun 2018 Planned End Date changed from 12 May 2020 to 31 Dec 2020.
    • 11 Jun 2018 Planned primary completion date changed from 12 Dec 2018 to 30 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top